Sunday, May 22, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Daiichi Sankyo Apologizes for Not Meeting Vaccine Production Milestone for Pandemic Preparedness

by Global Biodefense Staff
May 22, 2019
Influenza H1N1 Research

Daiichi Sankyo announced in an official statement on 17 May that the Company has been unable to fulfill its obligation to build a manufacturing supply system to supply vaccines for 40 million people in case of an epidemic in the time allotted under the Japanese Ministry of Health, Labour and Welfare’s cell culture vaccine production facility capacity building project.

The effort is a part of the Ministry’s second initiative for H5NI vaccine development and production capacity building grant. After being selected for the project, Daiichi Sankyo had been engaged in preparations to build a program to supply vaccines from August 2011 to March 31, 2019.

The drugmaker said they have been unable to build a scheme capable of supplying vaccines for 40 million people in 6 months by March 31, 2019, the extended time limit for the initiative, and the scheme built is now capable of supplying vaccines for approximately 23 million people.

Daiichi Sankyo apologized for having been unable to build the required infrastructure in the timeframe allotted and will be returning part of the national grant funding and paying a delinquency charge.

“Daiichi Sankyo and Daiichi Sankyo Biotech will make efforts toward maintaining and managing a scheme that will be fully capable of supplying the required quantity of H5NI influenza vaccine necessary for when a pandemic breaks out, and will contribute to the health of people in Japan,” noted the company.

Tags: Avian InfluenzaEditor PickH5N1InfluenzaPandemic

Related Posts

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster
Preparedness

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs
Medical Countermeasures

New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs

April 10, 2022
Yersinia pestis
Funding News

NIH Awards $3M Grant to Albany Med for Plague Vaccine Development

April 8, 2022
Troubling Trends in Physician Vaccine Confidence in the United States
Medical Countermeasures

Troubling Trends in Physician Vaccine Confidence in the United States

April 5, 2022
Load More

Latest News

NIH to Further Invest in Point-of-Care Technologies Research Network

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC